Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
about
Structural determinants of drugs acting on the Nav1.8 channelCRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathySynthesis and analgesic effects of μ-TRTX-Hhn1b on models of inflammatory and neuropathic pain.The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation.The role of sodium channels in chronic pain.Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed configuration.Sodium channel blockers for the treatment of neuropathic pain.Ion channel blockers for the treatment of neuropathic pain.Migraine and epilepsy: review of the literature.Regulation of the spontaneous augmentation of Na(V)1.9 in mouse dorsal root ganglion neurons: effect of PKA and PKC pathways.Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics.Novel modulator of Na(V)1.1 and Na(V)1.2 Na channels in rat neuronal cellsInhibition of voltage-gated sodium channels by sumatriptan bioisosteres.Effects of BmKNJX11, a bioactive polypeptide purified from Buthus martensi Karsch, on sodium channels in rat dorsal root ganglion neurons.The Selective Nav1.7 Inhibitor, PF-05089771, Interacts Equivalently with Fast and Slow Inactivated Nav1.7 Channels.CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain
P2860
Q24644825-8D49FA5C-BAB5-42E6-A9D7-D3D96B4BC72EQ30528512-4C5B49CE-5F79-47D9-83E3-1383F105A059Q34101792-10AF34EC-09E3-492C-ACB7-684E52D1CD47Q34359543-2F9E5012-3C6F-4D63-ACAF-1A77E534B43DQ36103777-E1377E90-627C-4109-997B-E9E373AC5DB2Q36914467-D8D7C7BC-1BCA-413C-A368-D81BB438A8B0Q37605350-A45947C7-F045-4D7E-9031-887A879CDDC5Q37855929-13E46354-B7A3-4AC6-9866-ADDE79539F99Q38371291-21586947-0E25-45B3-8D3F-E0F76DEB6081Q40113375-4DBD0DE9-7100-4D56-8D83-1BCE322C7EBFQ41444544-0B31B657-7299-41E6-809D-DA045BF97C63Q41584517-65DB825C-2486-41E3-87C5-0FF1B3A2A455Q42035720-6245FE78-EF36-48C9-92D5-5A4C6F6F7DF9Q44902773-1D99FC3E-6A39-49A4-9565-D6A7A877F68DQ47392507-CA4C620A-AC3E-4D64-B3F2-ABB07053134CQ58582878-09CEB8E8-8BDA-42C2-B01D-D20E75D20A5B
P2860
Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
@en
type
label
Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
@en
prefLabel
Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
@en
P2860
P1476
Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
@en
P2093
Anthony M Rush
Theodore R Cummins
P2860
P304
P356
10.1586/14737175.7.11.1597
P577
2007-11-01T00:00:00Z